Rehovot, Israel

Lev Goltsman

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Zetiq Technologies Ltd.. Active years: 2013.




Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lev Goltsman: Innovator in Cell Phenotyping

Introduction

Lev Goltsman is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of cell biology through his innovative methods and compositions for identifying cell phenotypes. His work is particularly relevant in the diagnosis of cancer and metabolic diseases.

Latest Patents

Goltsman holds 1 patent for his invention titled "Methods and compositions for identifying a cell phenotype." This patent describes a method of staining or pre-staining at least one cell by contacting it with a staining agent selected from a group that includes an extract of a plant, CHO, and proanthocyanidin. The method allows for the detection of cells at different differentiation stages, which is crucial for diagnosing various medical conditions.

Career Highlights

Lev Goltsman is associated with Zetiq Technologies Ltd., where he applies his expertise in cell phenotyping. His work at the company has positioned him as a key player in advancing technologies that enhance our understanding of cellular behavior and disease diagnosis.

Collaborations

Goltsman has collaborated with notable colleagues, including Dan Jacob Gelvan and Alexander Chausovsky. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Lev Goltsman's contributions to the field of cell biology through his patented methods for identifying cell phenotypes highlight his role as an influential inventor. His work continues to impact the medical field, particularly in the areas of cancer and metabolic disease diagnosis.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…